



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

Mail Stop 4720

August 13, 2015

Via E-mail

Eric d'Esparbes
Senior Vice President & Chief Financial Officer
Theravance, Inc.
951 Gateway Blvd.
South San Francisco, CA 94080

**Re: Theravance, Inc.
Form 10-K
Filed February 27, 2015
File No. 000-30319**

Dear Mr. d'Esparbes:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Daniel Greenspan for

Jeffrey P. Riedler
Assistant Director
Office of Healthcare and Insurance

cc: Via E-mail

Keith J. Scherer
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
One Marina Park Drive
Suite 900
Boston, MA 02210